This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Does Preoperative Caldolor Decrease the Requirement for Postoperative Narcotics

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2014 by Ronald S. Chamberlain, St. Barnabas Medical Center.
Recruitment status was:  Active, not recruiting
Cumberland Pharmaceuticals
Information provided by (Responsible Party):
Ronald S. Chamberlain, St. Barnabas Medical Center Identifier:
First received: November 15, 2010
Last updated: December 12, 2014
Last verified: December 2014

Caldolor® is an intravenous (IV) formulation of ibuprofen encompassing analgesic, anti-inflammatory and antipyretic (anti-fever) properties. Caldolor® is the first IV antipyretic approved by the US Food and Drug Administration (FDA), providing an alternate route for administration of ibuprofen when the oral route is not preferable. Recent studies have reported that Caldolor® decreases morphine use and pain at rest and with movement compared to patients not receiving this drug.

The hypothesis of the proposed study is that a single dose of Caldolor® 800 mg given 30 minutes preoperatively for patients undergoing laparoscopic or open inguinal and/or umbilical hernia repair will result in a >20% decrease in postoperative narcotic use within the first 24 hours and at 7 days, and decreased VAS Pain Score at 2 hours, 1 day, 3 days and 7 days after surgery. The use of less postoperative narcotics has been associated with a faster return of normal bowel function and resumption of normal ambulatory status thus resulting in improved general well being for the patient.

Condition Intervention Phase
Postoperative Pain Drug: Intravenous Ibuprofen Other: IV Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Supportive Care
Official Title: Does Preoperative Caldolor Decrease the Requirement for Postoperative Narcotics in Patients Undergoing Laparoscopic or Open Inguinal and/or Umbilical Hernia Repair? A Randomized, Double-Blind, Prospective Trial

Resource links provided by NLM:

Further study details as provided by Ronald S. Chamberlain, St. Barnabas Medical Center:

Primary Outcome Measures:
  • Postoperative Narcotic Use [ Time Frame: 7 days ]
    Post-operatively, the patient will receive a journal to record daily medication used up to and including post-operative day 7.

Secondary Outcome Measures:
  • Postoperative Visual Analog Pain Scale [ Time Frame: 7 days ]
    The patient will receive a Visual Analog Pain Scale to complete 2 hrs post-operatively, post-operative day 1, post-operative day 3 and post-operative day 7

Enrollment: 51
Study Start Date: February 2011
Estimated Study Completion Date: March 2015
Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: IV Caldolor Drug: Intravenous Ibuprofen
800 mg IV ibuprofen 30 minutes preoperatively
Other Name: Caldolor
Placebo Comparator: Placebo Other: IV Placebo
IV normal saline


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • primary inguinal and/or umbilical hernia repair
  • age > 18 years old

Exclusion Criteria:

  • history of gastrointestinal bleeding
  • allergy to ibuprofen
  • creatinine > 1.5 mg/dL
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01297829

United States, New Jersey
Saint Barnabas Medical Center
Livingston, New Jersey, United States, 07039
Sponsors and Collaborators
St. Barnabas Medical Center
Cumberland Pharmaceuticals
Principal Investigator: Ronald S Chamberlain, MD, MPA, FACS St. Barnabas Medical Center
  More Information

Responsible Party: Ronald S. Chamberlain, Chairman and Chief Department of Surgery, St. Barnabas Medical Center Identifier: NCT01297829     History of Changes
Other Study ID Numbers: 2010-11-15
Study First Received: November 15, 2010
Last Updated: December 12, 2014

Keywords provided by Ronald S. Chamberlain, St. Barnabas Medical Center:
postoperative narcotics
visual analog pain scale
inguinal hernia repair
umbilical hernia repair

Additional relevant MeSH terms:
Pain, Postoperative
Neurologic Manifestations
Nervous System Diseases
Postoperative Complications
Pathologic Processes
Signs and Symptoms
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Central Nervous System Depressants processed this record on August 17, 2017